Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties

[1]  M. Davids.  How should we sequence and combine novel therapies in CLL? , 2017, Hematology. American Society of Hematology. Education Program.

[2]  P. Martin.  Optimizing therapy for mantle cell lymphoma. , 2017, Hematology. American Society of Hematology. Education Program.

[3]  A. Logan,et al.  Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. , 2017, Blood.

[4]  N. Schmitz,et al.  Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial. , 2017, Blood.

[5]  J. Byrd,et al.  Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Z. Estrov,et al.  Long‐term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib , 2017, Cancer.

[7]  B. Cheson,et al.  Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  J. Delgado,et al.  Risk factors for treatment failure after allogeneic transplantation of patients with CLL: a report from the European Society for Blood and Marrow Transplantation , 2017, Bone Marrow Transplantation.

[9]  C. Pezzi,et al.  Chemotherapy Significantly Improves Survival for Patients with T1c-T2N0M0 Medullary Breast Cancer: 3739 Cases From the National Cancer Data Base , 2017, Annals of Surgical Oncology.

[10]  J. Woyach.  How I manage ibrutinib-refractory chronic lymphocytic leukemia. , 2017, Blood.

[11]  H. Putter,et al.  Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation , 2017, Bone Marrow Transplantation.

[12]  Jeffrey A Jones,et al.  BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  H. Tilly,et al.  Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC , 2016, Bone Marrow Transplantation.

[14]  M. Labopin,et al.  Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP–EBMT analysis on patients with AML in remission , 2016, Bone Marrow Transplantation.

[15]  R. Advani,et al.  Postibrutinib outcomes in patients with mantle cell lymphoma. , 2016, Blood.

[16]  J. Goldberg,et al.  Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study , 2016, The Lancet.

[17]  P. Hari,et al.  Long‐term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning , 2015, Cancer.

[18]  Michael L. Wang,et al.  Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. , 2015, Blood.

[19]  D. Porter,et al.  A drive through cellular therapy for CLL in 2015: allogeneic cell transplantation and CARs. , 2015, Blood.

[20]  M. Görner,et al.  Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapse , 2015, Bone Marrow Transplantation.

[21]  D. Chihara,et al.  Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  E. Kimby,et al.  Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents? , 2014, Blood.

[23]  J. Byrd,et al.  Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  J. Byrd,et al.  Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. , 2014, The New England journal of medicine.

[25]  S. Montoto,et al.  Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Jeffrey A Jones,et al.  Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. , 2013, Blood.

[27]  Michael L. Wang,et al.  Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. , 2013, The New England journal of medicine.

[28]  D. Blaise,et al.  Rituximab, fludarabine, and total body irradiation as conditioning regimen before allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukemia: long-term prospective multicenter study. , 2013, Experimental hematology.

[29]  J. Gribben,et al.  Long-Term Follow-up of Reduced Intensity Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia: Prognostic Model to Predict Outcome , 2012, Leukemia.

[30]  N. Schmitz,et al.  Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. , 2010, Blood.

[31]  B. Sandmaier,et al.  Defining the intensity of conditioning regimens: working definitions. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[32]  J. Radich,et al.  Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  W. Siegert,et al.  Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  R. Brand,et al.  Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning , 2003, Leukemia.

[35]  Jeffrey A Jones,et al.  Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. , 2018, The Lancet. Oncology.